What's Going On With Tharimmune Shares Monday?
What's Going On With Tharimmune Shares Monday?
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Tharimmune, Inc. (NASDAQ:THAR) shares initially traded higher on Monday, but have since reversed after the company presented clinical data at the 75th American Association for the Study of Liver Disease (AASLD) meeting. Here's what you need to know.
Tharimmune, Inc.（纳斯达克：THAR）股票周一最初交易上涨，但在公司在第75届美国肝病研究协会（AASLD）会议上呈现临床数据后已回落。以下是您需要了解的内容。
What To Know: Tharimmune, a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, presented positive clinical data from a Phase I trial of TH104, a potential treatment for chronic pruritus in chronic liver disease.
Tharimmune是一家处于临床阶段的生物技术公司，正在开发一系列用于炎症和免疫学的治疗候选药物，呈现了TH104的I期试验的积极临床数据，这是一种用于慢性肝病中慢性瘙痒的潜在治疗。
The clinical data showed that higher levels of TH104 in the blood were associated with a reduction in itching, a common symptom of chronic pruritus. The treatment also appeared safe, with no serious side effects reported.
临床数据表明，血液中较高水平的TH104与瘙痒的减轻有关，而瘙痒是慢性瘙痒的常见症状。该治疗似乎也很安全，没有报告严重副作用。
"We look forward to initiating a Phase 2 multiple-ascending dose trial in the coming months to evaluate TH104 in chronic pruritus in primary biliary cholangitis (PBC) patients, with topline data expected in 2025. In the meantime, we continue to engage with both U.S. and EU regulatory authorities," said Randy Milby, CEO of Tharimmune.
“我们期待在接下来的几个月内启动针对原发性胆汁性胆管炎（PBC）患者慢性瘙痒的II期多升剂量试验，预期在2025年获得总结数据。与此同时，我们将继续与美国和欧盟监管机构进行接触，”Tharimmune首席执行官Randy Milby说道。
How To Buy THAR Shares
如何购买THAR股票
By now you're likely curious about how to participate in the market for Tharimmune – be it to purchase shares, or even attempt to bet against the company.
现在您可能好奇如何参与Tharimmune的市场——无论是购买股票，还是尝试对抗该公司。
Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy 'fractional shares,' which allows you to own portions of stock without buying an entire share.
购买股票通常通过券商账户完成。您可以在这里找到可能的交易平台列表。许多平台允许您购买“碎股”，这使您无需购买整股就可以拥有部分股票。
In the case of Tharimmune, which is trading at $1.93 as of publishing time, $100 would buy you 51.81 shares of stock.
就Tharimmune而言，截至出版时交易价格为1.93美元，100美元将为您购买到51.81股股票。
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to 'go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.
如果您想押注股票下跌，流程就更为复杂了。您需要访问期权交易平台，或者找一家券商让您通过借出股票进行“开空”操作（借股出售）。您可以在该资源中了解到卖空股票的过程。否则，如果您的券商允许您交易期权，您可以在当前股票交易价以上的执行价上购买看跌期权或者卖出看涨期权 - 无论哪种情况都可以让您从股票价格下跌中获利。
THAR Price Action: At the time of publication, Tharimmune shares were down 8.29% at $1.99, according to data from Benzinga Pro.
THAR价格走势：根据Benzinga Pro的数据，在发布时，Tharimmune的股价下跌了8.29%，报1.99美元。
Image: Photo by roberto-sorin for Unsplash
图片：由roberto-sorin提供的Unsplash
